Hadasit Bio Holdings Ltd. (TASE:HDST) and Anadis, Ltd. (ASX: ANX) announced today their intention to form a new joint venture company tentatively called Immuron. The mandate of the new company is to develop a new line of therapeutic products for the treatment of several inflammatory diseases, infectious diseases, and cancers.
The products will be based on a combination of intellectual property (IP) from Hadasit and Anadis. Hadasit will contribute user specific methods for the treatment of immune mediated disorders and cancer.
“Hadasit is well known for its enormous pool of IP. It also has a superb reputation as a center of excellence for pre-clinical and early stage clinical practice.” said Dr. Oren Fuerst, VP for Business Development at Anadis and CEO of Immuron.
Pre-clinical studies will begin in January to determine the efficacy of the products in animal models. Phase I clinical trials are anticipated to begin in the second half of 2009. The pre-clinical, Phase I and Phase II studies will be conducted at Hadasit at the new Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem. The custom manufacturing of the commercial products will be conducted by Anadis and new intellectual property will be licensed back to Anadis for use in its additional research initiatives.
Anadis, Ltd. is a research-driven biotechnology company focused on antibody-based health products. Anadis has developed a product pipeline of polyclonal antibody-based solutions to a range of important infectious and immune-mediated diseases.
Hadasit is the technology transfer company of Hadassah Medical Organization (HMO) in Jerusalem.
Published by Globes [online], Israel business news - www.globes-online.com - on November 14, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007